

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP			
2. Address Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>			
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____			
4a. Contact Name Ms. <u>Sarah Arbes</u>	b. Telephone Number <u>2022467003</u>	c. E-mail <u>sarah.arbes@astrazeneca.com</u>	5. Senate ID# <u>54073-12</u>
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP			6. House ID# <u>349750000</u>

TYPE OF REPORT 8. Year 2024 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center">12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>700,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Sarah Arbes Date 4/22/2024 3:08:34 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R.7085 Biosecure Act
 H.R. 5539/S.3131 ORPHAN Cures Act, expanding orphan drug exclusion in IRA
 H.R.5378, the LOWER COSTS, MORE TRANSPARENCY ACT, In Senate - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (Better Act), Pharmacy Benefit Manager Reform Act

Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties

Patent listings of drug-device combinations
 Reauthorization of newborn screening programs
 Reauthorization of the pediatric priority review voucher program
 RSV Vaccine issues
 FDA modernization policy issues
 Medicare drug price negotiation
 Medicaid Drug Rebate Program proposed rule
 PBM Reform (misc. bills)

Issues related to reform of pharmacy benefit managers
 Issues related to FDA proposed regulation of lab developed tests
 Issues related to the orphan drug exclusion of the Inflation Reduction Act
 Issues related to the price and manufacture of inhaled medicines
 Issues related to march-in rights
 Issues related to drug pricing
 Issues related to importation of drugs

Sustainability issues as a general topic
 General issues related to health equity in rare disease and clinical trials
 General issues related to diagnostics for patients with rare diseases
 General issues related to rare disease and orphan drugs

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta		Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 5539 Orphan Cures Act, (expanding orphan drug exclusion in IRA)
 H.R. 3876 Access to Genetic Counselor Services Act of 2023
 H.R. 2666 Medicaid VBPs for Patients Act
 H.R. 5539 Orphan Cures Act, (expanding orphan drug exclusion in IRA)

Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No 117-169)
 Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169

CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure

Centers for Medicare and Medicaid Innovation (CMMI) policy issues
 Value-based payment arrangements
 Medicare patient access to rare disease therapies, Part B and Part D drugs
 Medicaid Drug Rebate Program proposed rule, specifically the stacking rule
 Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies
 General issues related to diagnostic reimbursement
 Value-based payment arrangements
 Efforts to improve coding, coverage, and access for rare disease therapies

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta		Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to Pharmacy Benefit Managers (PBMs)
 Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta		Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 1350, Camerons Law
 H.R. 5376 – Share the Savings with Seniors Act
 S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

 Issues related to the Orphan Drug Tax Credit;
 issues related to the deduction of research and development expenditures

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta		Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform TRIPS Waiver General patent issues Issues related to pharmaceutical intellectual property (IP)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta		Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

--

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

	First Name	Last Name	Suffix		First Name	Last Name	Suffix
1	Elizabeth	Brooks		3			
2				4			

ISSUE UPDATE

24. General lobbying issue that no longer pertains

--	--	--	--	--	--	--	--	--

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address	City	State/Province	Zip	Country	
						City State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1	2	3
----------	----------	----------

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	City	State/Province			
				City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	3	5
2	4	6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)